Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Articles by Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Treatment Landscape for Transplant-Eligible Patients with NDMM
ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP,C. Brooke Adams, PharmD, BCOP Panelists discuss how the current first-line treatment options for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) typically involve combination therapies including proteasome inhibitors, immunomodulatory drugs, and steroids.
In her first Editor’s Note as editor in chief of PPFO, Zahra Mahmoudjafari shares reflections on a summer filled with conferences.
